PEARL Study: PotEntial of Asciminib in the eaRly Treatment of CML

The PEARL study tests asciminib — a newer type of targeted drug — in patients recently diagnosed with chronic myeloid leukemia (CML, a blood cancer). Asciminib works differently from older CML drugs, and this study looks at whether using it early leads to better long-term remission. **You may be eligible if...** - You are 18 or older - You have been newly diagnosed with Philadelphia chromosome-positive CML in chronic phase within the past 3 months - You have had little to no prior treatment (30 days or fewer of TKI therapy; hydroxyurea or anagrelide is allowed) - Your organ function is adequate **You may NOT be eligible if...** - You have had more than 30 days of TKI therapy - Your CML is in an accelerated or blast phase - You have serious heart conditions (e.g., recent heart attack, certain rhythm problems) Talk to your doctor to see if this trial is right for you.